SCHEMBL6480917

SCHEMBL6480917

Cc1cc2cc(NC(=O)C3CC3)ccc2n1C(=O)c1c(F)cccc1C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 1/20 0.46
ACKR3 P25106 1/20 0.42
MAPT P10636 2/20 0.41
KMT2A Q03164 4/20 0.41
MEN1 O00255 3/20 0.41
ALDH1A1 P00352 1/20 0.41
HSD17B10 Q99714 2/20 0.40
KDR P35968 3/20 0.40
UBE2M P61081 1/20 0.39
DCUN1D1 Q96GG9 1/20 0.39
POLB P06746 1/20 0.39
KDM4E B2RXH2 2/20 0.39
USP2 O75604 1/20 0.39
LMNA P02545 1/20 0.39
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
EGFR P00533 1/20 0.39
ERBB4 Q15303 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6480678 0.96 ACKR3 (0.44) RORCACKR3MAPTKMT2AMEN1
SCHEMBL6480480 0.96 RORC (0.43) RORCACKR3MAPTKMT2AMEN1
SCHEMBL6492171 0.95 ACKR3 (0.46) RORCACKR3MAPTKMT2AMEN1
SCHEMBL6489116 0.91 HSD17B10 (0.44) MAPTKMT2AMEN1HSD17B10USP2
SCHEMBL6480758 0.90 PARP1 (0.42) RORCACKR3MAPTKMT2AMEN1
SCHEMBL6490688 0.87 MGLL (0.44) RORCMAPTKMT2AMEN1HSD17B10
SCHEMBL6480722 0.87 NPSR1 (0.49) ALDH1A1HSD17B10KDM4ELMNASMN1; SMN2
SCHEMBL6480771 0.87 NPSR1 (0.46) MAPTALDH1A1HSD17B10POLBKDM4E
SCHEMBL6492402 0.84 NPSR1 (0.46) ALDH1A1TSHRSMN1; SMN2MALT1
SCHEMBL6489974 0.84 JAK2 (0.43) MAPTKMT2AHSD17B10SMN1; SMN2MALT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050215614-A1 Substituted indoles and their use as hcv inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215614-A1 Substituted indoles and their use as hcv inhibitors IDO1, IDO2, HAVCR2 RORC 387/4885ACKR3 895/4885MAPT 3587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.